Naxicap Partners has acquired Groupe Moria
Naxicap Partners has acquired Groupe Moria from Bridgepoint Development Capital.
Naxicap Partners is a French private equity firm operating in all sectors and focusing on leverage buy-outs and growth capital. For more than 30 years, the firm has invested in ambitious companies in France, Benelux and Spain through controlling majority stakes. As of 31/12/2017, Naxicap Partners manages US$3.5 billion for BPCE Group (33%) and for global institutional investors (67%).
Groupe Moria manufactures and distributes ophthalmic surgery consumables, single use and reusable instruments addressing refractive, corneal, cataract and retinal procedures. The company benefits from strong know-how, combining handcraft capabilities and state-of-the-art technology located in two industrial facilities in France. Present in nearly 80 countries, the group reaches its end customers worldwide through to a tier-2 distribution model (direct sales to surgeons and healthcare facilities and indirect sales via distributors and wholesalers).
Bridgepoint Development Capital is a major international private equity group focused on buy-outs and growth capital investments, typically in businesses with an enterprise value of between US$22–267 million. The firm currently operates in the UK, France and the Nordic region.
Oaklins' team in France advised the buyer in this transaction.
Talk to the deal team
Armelle Brossard Laborderie
Groupe Nature acquires Winco
Groupe Nature has signed an agreement with Nicolas Watine, founder and CEO of Winco, to acquire his stake in the comany. It specializes in the distribution of health and cosmetic products in parapharmacies affiliated to supermarket chains. This acquisition strengthens Groupe Nature’s position as a multi-channel specialist in the distribution of organic health products.Learn more
Camelia pharmacy chain has been acquired by Medigate Management UAB
CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.Learn more
Shield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.Learn more